Oppenheimer Downgrades Raptor Pharmaceutical To Underperform

Analysts at Oppenheimer downgraded

from Perform to Underperform. Raptor Pharmaceutical shares have gained 46.75 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period. Raptor Pharmaceutical's shares fell 7.54 percent to $14.60 in pre-market trading.